: iStockAnalyst.com Symbols Feed

PicksThatMove.Com Announces Investment Opinion: Hot Stocks on the Move

Tue, 29 Sep 2009 19:48:00 GMT

PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation.
To view some of our profiled stocks, please visit our website at www.picksthatmove.com.
The investment opinions offered below and in this press release are provided by Nick Hunter, RIA, of PicksThatMove.com

[More...]

Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance

Tue, 22 Sep 2009 13:47:00 GMT

Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, today announced that on September 16, 2009, as management expected, the Company received a letter from The Nasdaq Stock Market notifying the Company that for the last 30 consecutive business days the bid price of the Company's common stock closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Market under Nasdaq Rule 5450(a)(1).
In order to regain compliance, shares of the Company's common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of ten consecutive business days during the grace period.
About Marshall Edwards, Inc.

[More...]

Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited

Wed, 05 Aug 2009 12:00:00 GMT

NEW CANAAN, CT and SYDNEY, AUSTRALIA -- -- 08/05/09 -- Novogen Limited and Marshall Edwards, Inc. have concluded a license agreement for Marshall Edwards to develop and commercialize the oncology compound NV-128.[More...]

Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells

Tue, 07 Jul 2009 11:56:00 GMT

NEW CANAAN, CT and SYDNEY, AUSTRALIA -- -- 07/07/09 -- Researchers at the Malaghan Institute of Medical Research in Wellington, New Zealand have found that abnormally proliferating human T-cells, rapidly dividing cancer cells such as primary myeloid and lymphoid leukemic blast cells undergo programmed cell death when exposed briefly to the investigational anti-tumor drug phenoxodiol.[More...]

Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial

Wed, 17 Jun 2009 12:25:00 GMT

NEW CANAAN, CT -- -- 06/17/09 -- The Independent Data Monitoring Committee created to oversee the conduct of the Phase III OVArian TUmor REsponse Trial, which convened during the recent Annual Meeting of the American Society of Clinical Oncology, considered the data accumulated to date and reviewed the arrangements announced by the Company for early termination of patient enrollment into the study.[More...]

Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial

Tue, 14 Apr 2009 12:15:00 GMT

NEW CANAAN, CT and SYDNEY, AUSTRALIA -- -- 04/14/09 -- Marshall Edwards, Inc., today announced that it will be undertaking an un-blinded analysis of the data from its Phase III international, multicenter clinical study known as 'Ovature' .[More...]

Board Changes at Novogen Limited Announced - Mar 23 2009 12:55PM

Mon, 23 Mar 2009 16:50:00 GMT

Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William D. Rueckert to its Board of Directors.
The advantage for Novogen of Mr. Rueckert becoming a director is that he is already familiar with the group, having been a director for two years on the boards of subsidiaries, Glycotex and Marshall Edwards, and brings considerable U.S. based commercial experience.
Mr. Rueckert is the Managing Member of Oyster Management Group, LLC and is a director of Glycotex, Inc., an 83 percent owned unlisted subsidiary of Novogen Limited.

[More...]

Board Changes at Novogen Limited Announced - Mar 23 2009 11:02AM

Mon, 23 Mar 2009 14:41:00 GMT

NEW CANAAN, CT and SYDNEY, AUSTRALIA -- -- 03/23/09 -- Novogen Limited is pleased to announce the appointment of Mr. William D. Rueckert to its Board of Directors.[More...]

Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.

Thu, 19 Mar 2009 17:03:00 GMT

NEW CANAAN, CT and SYDNEY, AUSTRALIA -- -- 03/19/09 -- Marshall Edwards, Inc. is pleased to announce the appointment of Leah Cann to the Board of Directors of the Company.[More...]

Novogen's NV-128 Targets the mTOR Pathway to Induce Cell Death in Epithelial Ovarian Cancer Stem Cells

Wed, 18 Mar 2009 15:11:00 GMT

NEW CANAAN, CT -- -- 03/18/09 -- NV-128, a Novogen, Ltd. compound, induced cell death in ovarian cancer stem cells in a dose-dependent manner. The study will be presented by Ayesha Alvero, M.D., of Yale University School of Medicine, Department of Obstetrics, Gynecology and Reproductive Science, at the 2009 Annual Meeting of the American Association for Cancer Research in Denver, April 18-22. Because ovarian cancer stem cells usually survive conventional chemotherapy, these cells are considered to be the potential source of recurrence. It appears that NV-128 promotes cell death in these cancer stem cells through inhibition of the mTOR and other pathways. These findings may open up a new avenue for treating ovarian cancer patients who become resistant to chemotherapy.[More...]

Form 4 MARSHALL EDWARDS INC For: May 18 Filed by: JOHNSTON PHILIP A (10K)

Tue, 08 Sep 2009 16:04:00 GMT

[More...]

Form 4 MARSHALL EDWARDS INC For: Nov 20 Filed by: Rueckert William Dodge (10K)

Tue, 25 Nov 2008 02:11:00 GMT

[More...]

Form 4 MARSHALL EDWARDS INC For: Nov 18 Filed by: Rueckert William Dodge (10K)

Thu, 20 Nov 2008 15:52:00 GMT

[More...]

Form 4 MARSHALL EDWARDS INC For: Mar 13 Filed by: Williams Bryan (10K)

Wed, 24 Sep 2008 17:24:00 GMT

[More...]

Form 4 MARSHALL EDWARDS INC For: Jul 28 Filed by: NOVOGEN LTD (10K)

Wed, 30 Jul 2008 23:58:00 GMT

[More...]